Market Place
Sourcing Support
Vaccinex Update on ActivMAb® Platform & SITC Presentation
07 Nov 2024 //
GLOBENEWSWIRE
Vaccinex Reports Immunity Benefit with Pepinemab at SITC Meeting
05 Nov 2024 //
GLOBENEWSWIRE
Vaccinex Reports SIGNAL-AD Data for Pepinemab at CTAD
31 Oct 2024 //
GLOBENEWSWIRE
Vaccinex To Report Efficacy Data For SIGNAL-AD Trial At CTAD
24 Oct 2024 //
GLOBENEWSWIRE
Vaccinex Announces $6.2M From Warrant Exercise
18 Sep 2024 //
GLOBENEWSWIRE
Vaccinex Updates SIGNAL-AD Phase 1b/2 Trial Findings For Alzheimer`s Disease
14 Aug 2024 //
GLOBENEWSWIRE
Vaccinex Reports Positive Phase 1b/2 Data For Pepinemab In Alzheimer`s
31 Jul 2024 //
GLOBENEWSWIRE
Vaccinex To Present Alzheimer`s Trial Data At AAIC On July 31
17 Jul 2024 //
GLOBENEWSWIRE
Vaccinex Reports Last Patient Visit In SIGNAL-AD Pepinemab Alzheimer`s Trial
06 Jun 2024 //
GLOBENEWSWIRE
Vaccinex Reports Q1 2024 Financial Results, Corporate Update
15 May 2024 //
GLOBENEWSWIRE
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
02 Apr 2024 //
GLOBENEWSWIRE
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering
27 Mar 2024 //
GLOBENEWSWIRE
Vaccinex Announces Agreements for Access to ActivMAb® Antigen Virus Technology
21 Feb 2024 //
GLOBENEWSWIRE
Vaccinex, Inc. Announces Reverse Stock Split
15 Feb 2024 //
GLOBENEWSWIRE
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
07 Feb 2024 //
GLOBENEWSWIRE
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance
04 Dec 2023 //
GLOBENEWSWIRE
Vaccinex Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Vaccinex Reports Benefit in Analyses from two Phase 2 Studies of Pepinemab
31 Oct 2023 //
GLOBENEWSWIRE
Vaccinex Reports Effect of Pepinemab Treatment in Neurodegenerative Diseases
26 Oct 2023 //
GLOBENEWSWIRE
Vaccinex Announces Pricing of $9.6 Million Public Offering
28 Sep 2023 //
GLOBENEWSWIRE
Vaccinex™s Next Generation ActivMAb® Technology Published in mAbs
28 Sep 2023 //
GLOBENEWSWIRE
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
27 Sep 2023 //
GLOBENEWSWIRE
Vaccinex Reports Groundbreaking Findings at Medical Conferences
26 Sep 2023 //
GLOBENEWSWIRE
Vaccinex, Inc. Announces Reverse Stock Split
22 Sep 2023 //
GLOBENEWSWIRE
Vaccinex Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Vaccinex Reports 1Q 2023 FYR Results and Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD
25 Apr 2023 //
GLOBENEWSWIRE
Vaccinex ActivMAb application published in Nature Communications
12 Apr 2023 //
GLOBENEWSWIRE
Vaccinex Reports 2022 Financial Results
03 Apr 2023 //
GLOBENEWSWIRE
Vaccinex Announces Private Placement with Commitments of $5.0 Million
03 Apr 2023 //
GLOBENEWSWIRE
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
23 Mar 2023 //
GLOBENEWSWIRE
Vaccinex Announces Initiation of Phase Ib/2 Study to Evaluate Pepinemab
21 Mar 2023 //
GLOBENEWSWIRE
Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment
09 Mar 2023 //
GLOBENEWSWIRE
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody
09 Jan 2023 //
GLOBENEWSWIRE
Vaccinex Announces $3.8 Million Private Placement
28 Nov 2022 //
GLOBENEWSWIRE
Vaccinex Reports Third Quarter 2022 Results and Provides Corporate Update
14 Nov 2022 //
GLOBENEWSWIRE
Vaccinex and its Collaborators Present Two Abstracts to Pepinemab Combination
10 Nov 2022 //
GLOBENEWSWIRE
Vaccinex Reports Second Quarter 2022 Results and Provides Corporate Update
15 Aug 2022 //
GLOBENEWSWIRE
Vaccinex’s PII “SIGNAL” Study to Evaluate Pepinemab Ab in Huntington’s Disease
08 Aug 2022 //
GLOBENEWSWIRE
Vaccinex to Present at the 2022 AAIC Updating the SIGNAL-AD Study of Pepinemab
29 Jul 2022 //
GLOBENEWSWIRE
Vaccinex to Participate in the Jefferies Healthcare Conference
25 May 2022 //
GLOBENEWSWIRE
Vaccinex Reports First Quarter 2022 Results and Provides Corporate Update
16 May 2022 //
GLOBENEWSWIRE
Vaccinex, Announces Upcoming Presentation at the PEGS Boston Conference & Expo
25 Apr 2022 //
GLOBENEWSWIRE
Vaccinex Reports 2021 Financial Results and Provides Corporate Update
31 Mar 2022 //
GLOBENEWSWIRE
Vaccinex Reports positive interim response data in Phase Ib of KEYNOTE-B84 study
26 Jan 2022 //
GLOBENEWSWIRE
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda & Pepinemab
04 Jan 2022 //
GLOBENEWSWIRE
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC)
10 Nov 2021 //
GLOBENEWSWIRE
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD)
09 Nov 2021 //
GLOBENEWSWIRE
Vaccinex Reports 3Q2021 Financial Results and Provides Corporate Update
08 Nov 2021 //
GLOBENEWSWIRE
Vaccinex to Present at the Virtual Huntington’s Study Group on Nov4-6, 2021
01 Nov 2021 //
GLOBENEWSWIRE
Vaccinex to Present at Oppenheimer Fall Healthcare Summit
17 Sep 2021 //
GLOBENEWSWIRE
Vaccinex CEO Presented New and Promising Phase 2 SIGNAL Trial Data
15 Sep 2021 //
GLOBENEWSWIRE
Vaccinex Reports Second Quarter 2021 Financial Results
16 Aug 2021 //
GLOBENEWSWIRE
Vaccinex to Chair Panel Q&A Session & Present Poster at the XV European Meeting
30 Jun 2021 //
GLOBENEWSWIRE
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2
21 Apr 2021 //
VACCINEX
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology
22 Feb 2021 //
GLOBENEWSWIRE
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study
29 Oct 2020 //
GLOBENEWSWIRE
Vaccinex`s drug misses the mark in Huntington phII; focus shifts to Alzheimer`s
22 Sep 2020 //
FIERCE BIOTECH
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
27 Aug 2020 //
GLOBENEWSWIRE
